IgE Reactivity Pattern to Timothy and Birch Pollen Allergens in Finnish and Russian KareliaMovérare R.a · Petäys T.b · Vartiainen E.c · Haahtela T.b
aPharmacia Diagnostics AB and Uppsala University, Department of Medical Sciences, Respiratory Medicine and Allergology, Uppsala, Sweden; bHelsinki University Central Hospital, Division of Allergy, and cDepartment of Epidemiology and Health Promotion, National Public Health Institute, Helsinki, Finland
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: Little is known about differences in IgE reactivity patterns to individual allergens in random populations. We studied the IgE reactivity profile to individual recombinant (r) and native (n) allergens in sera from subjects sensitized to timothy and/or birch pollen living in Finnish and Russian Karelia. Methods: Sera from IgE-sensitized adults were obtained from an epidemiological study on a random sample of 1,177 subjects. The IgE reactivity to pollen extracts and eight timothy (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4) and three birch pollen allergens (rBet v 1, 2 and 4) were analyzed with UniCAP®. Results: The levels of IgE antibodies to timothy and birch pollen were higher in Finnish (median 5.2, range 0.35 to >100 kUA/l,) than in Russian Karelia (median 1.8 kUA/l, range 0.43–25.2 kUA/l, p < 0.01). There was a significantly higher prevalence of IgE reactivity to three timothy pollen allergens in Finnish (n = 57) than in Russian Karelia (n = 12): rPhl p 2, 28 vs. 0%; rPhl p 5, 60 vs. 0%; rPhl p 6, 47 vs. 0%. The prevalence of IgE reactivity to the birch pollen allergens was similar in the two populations. IgE reactivity to rPhl p 2, 5, 6 and 11 was associated with hay fever symptoms. The timothy-pollen-specific serum IgE levels and the numbers of IgE reactivities to individual allergens correlated significantly (rs = 0.87, p < 0.0001). Conclusions: The data indicate that timothy- and birch pollen-specific IgE levels are higher in Finnish compared to Russian Karelia. This is reflected in wider IgE reactivity to individual timothy pollen allergens in Finnish Karelia, including the major allergen Phl p 5, and increased pollen allergy.
© 2005 S. Karger AG, Basel
- Kosunen TU, Hook-Nikanne J, Salomaa A, Sarna S, Aromaa A, Haahtela T: Increase of allergen-specific immunoglobulin E antibodies from 1973 to 1994 in a Finnish population and a possible relationship to Helicobacter pylori infections. Clin Exp Allergy 2002;32:373–378.
- von Mutius E, Martinez FD, Fritzsch C, Nicolai T, Roell G, Thiemann HH: Prevalence of asthma and atopy in two areas of West and East Germany. Am J Respir Crit Care Med 1994;149:358–364.
- Braback L, Breborowicz A, Dreborg S, Knutsson A, Pieklik H, Bjorksten B: Atopic sensitization and respiratory symptoms among Polish and Swedish school children. Clin Exp Allergy 1994;24:826–835.
- Bjorksten B, Dumitrascu D, Foucard T, Khetsuriani N, Khaitov R, Leja M, Lis G, Pekkanen J, Priftanji A, Riikjarv MA: Prevalence of childhood asthma, rhinitis and eczema in Scandinavia and Eastern Europe. Eur Respir J 1998;12:432–437.
- Vartiainen E, Petays T, Haahtela T, Jousilahti P, Pekkanen J: Allergic diseases, skin prick test responses, and IgE levels in North Karelia, Finland, and the Republic of Karelia, Russia. J Allergy Clin Immunol 2002;109:643–648.
Ahti T, Hämet-Ahti L, Jalas J: Vegetation zones and their sections in northwestern Europe. Ann Bot Fennici 1968;5:169–211.
- Moverare R, Westritschnig K, Svensson M, Hayek B, Bende M, Pauli G, Sorva R, Haahtela T, Valenta R, Elfman L: Different IgE reactivity profiles in birch pollen-sensitive patients from six European populations revealed by recombinant allergens. An inprint of local sensitization. Int Arch Allergy Immunol 2002;128:325–335.
- Mari A, Wallner M, Ferreira F: Fagales pollen sensitization in a birch-free area: A respiratory cohort survey using Fagales pollen extracts and birch recombinant allergens (rBet v 1, rBet v 2, rBet v 4). Clin Exp Allergy 2003;33:1419–1428.
- Laffer S, Spitzauer S, Susani M, Pairleitner H, Schweiger C, Gronlund H, Menz G, Pauli G, Ishii T, Nolte H, Ebner C, Sehon AH, Kraft D, Eichler HG, Valenta R: Comparison of recombinant timothy grass pollen allergens with natural extract for diagnosis of grass pollen allergy in different populations. J Allergy Clin Immunol 1996;98:652–658.
- Andersson K, Lidholm J: Characteristics and immunobiology of grass pollen allergens. Int Arch Allergy Immunol 2003;130:87–107.
- Niederberger V, Laffer S, Froschl R, Kraft D, Rumpold H, Kapiotis S, Valenta R, Spitzauer S: IgE antibodies to recombinant pollen allergens (Phl p 1, Phl p 2, Phl p 5, and Bet v 2) account for a high percentage of grass pollen-specific IgE. J Allergy Clin Immunol 1998;101:258–264.
- Petersen A, Bufe A, Schramm G, Schlaak M, Becker WM: Characterization of the allergen group VI in timothy grass pollen (Phl p 6). II. cDNA cloning of Phl p 6 and structural comparison to grass group V. Int Arch Allergy Immunol 1995;108:55–59.
- Petersen A, Bufe A, Schlaak M, Becker WM: Characterization of the allergen group VI in timothy grass pollen (Phl p 6). I. Immunological and biochemical studies. Int Arch Allergy Immunol 1995;108:49–54.
- Stumvoll S, Lidholm J, Thunberg R, DeWitt AM, Eibensteiner P, Swoboda I, Bugajska-Schretter A, Spitzauer S, Vangelista L, Kazemi-Shirazi L, Sperr WR, Valent P, Kraft D, Valenta R: Purification, structural and immunological characterization of a timothy grass (Phleum pratense) pollen allergen, Phl p 4, with cross-reactive potential. Biol Chem 2002;383:1383–1396.
- Mari A: Skin test with a timothy grass (Phleum pratense) pollen extract vs. IgE to a timothy extract vs. IgE to rPhl p 1, rPhl p 2, nPhl p 4, rPhl p 5, rPhl p 6, rPhl p 7, rPhl p 11, and rPhl p 12: Epidemiological and diagnostic data. Clin Exp Allergy 2003;33:43–51.
- Jarolim E, Rumpold H, Endler AT, Ebner H, Breitenbach M, Scheiner O, Kraft D: IgE and IgG antibodies of patients with allergy to birch pollen as tools to define the allergen profile of Betula verrucosa. Allergy 1989;44:385–395.
- Kazemi-Shirazi L, Niederberger V, Linhart B, Lidholm J, Kraft D, Valenta R: Recombinant marker allergens: Diagnostic gatekeepers for the treatment of allergy. Int Arch Allergy Immunol 2002;127:259–268.
- Wensing M, Akkerdaas JH, van Leeuwen WA, Stapel SO, Bruijnzeel-Koomen CA, Aalberse RC, Bast BJ, Knulst AC, van Ree R: IgE to Bet v 1 and profilin: Cross-reactivity patterns and clinical relevance. J Allergy Clin Immunol 2002;110:435–442.
- Kalyoncu AF, Stalenheim G: Serum IgE levels and allergic spectra in immigrants to Sweden. Allergy 1992;47:277–280.
- Krause T, Koch A, Friborg J, Poulsen LK, Kristensen B, Melbye M: Frequency of atopy in the Arctic in 1987 and 1998. Lancet 2002;360:691–692.
- Davies RJ, Rusznak C, Devalia JL: Why is allergy increasing? Environmental factors. Clin Exp Allergy 1998;28(suppl 6):8–14.
- Rimpela AH, Savonius B, Rimpela MK, Haahtela T: Asthma and allergic rhinitis among Finnish adolescents in 1977–1991. Scand J Soc Med 1995;23:60–65.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.